Search results
Showing 61 to 66 of 66 results for etanercept
Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)
This guidance has been updated and replaced by NICE technology appraisal guidance 373.
Discontinued [GID-TAG402]
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
NICE recommends several treatment options to help with rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.